Economic impact of GPIIB/IIIA blockade after high-risk angioplasty

This publication has 12 references indexed in Scilit:

• A Comparison of Aspirin plus Tirofiban with Aspirin plus Heparin for Unstable Angina
  New England Journal of Medicine, 1998
• Inhibition of the Platelet Glycoprotein IIb/IIIa Receptor with Tirofiban in Unstable Angina and Non–Q-Wave Myocardial Infarction
  New England Journal of Medicine, 1998
• Effects of Platelet Glycoprotein IIb/IIIa Blockade With Tirofiban on Adverse Cardiac Events in Patients With Unstable Angina or Acute Myocardial Infarction Undergoing Coronary Angioplasty
  Circulation, 1997
• Glycoprotein IIb/IIIa Receptor Inhibitors: Putting the EPIC, IMPACT II, RESTORE, and EPILOG Trials into Perspective
  The American Journal of Cardiology, 1996
• A Comparison of the Costs of and Quality of Life After Coronary Angioplasty or Coronary Surgery for Multivessel Coronary Artery Disease
  Circulation, 1995
• Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of the Platelet Integrin Glycoprotein IIb/IIIa Blocker Integrelin in Elective Coronary Intervention
  Circulation, 1995
• Use of a Monoclonal Antibody Directed against the Platelet Glycoprotein IIb/IIIa Receptor in High-Risk Coronary Angioplasty
  New England Journal of Medicine, 1994
• Multicenter investigation of coronary stenting to treat acute or threatened closure after percutaneous transluminal coronary angioplasty: Clinical and angiographic outcomes
  Journal of the American College of Cardiology, 1993
• Recent changes in the management and outcome of acute closure after percutaneous transluminal coronary angioplasty
  The American Journal of Cardiology, 1993
• Angiographic and clinical predictors of acute closure after native vessel coronary angioplasty.
  Circulation, 1988